



2018 December

Resident's Corner: Stoma problems




2018 December

What is the Cancer Risk with AIN III ?



2018 December

Expectant Management of HGAIN in HIV+ Pts



2018 December

Testing for HPV Subtypes 16/18 Predicts HSIL Lesions

894 consecutive patients undergoing screening for anal dysplasia

DRE, Cytology, High-Risk HPV Subtype Testing, Hi-Res Anoscopy + Biopsy



92% MSM



44% HIV+ on HAART




HSIL more prevalent when HPV 16/18 detected




PPV: 37%

HPV 16/18 assoc with: 31-fold increased risk of HSIL



Copyright © Wolters Kluwer Health, Inc. All rights reserved.

Sambursky JA et al. *Dis Colon Rectum* 2018;61(12):1364-71



2018 December

Rectal Neuroendocrine Tumors: Predictors of Metastases

4,893 patients with rectal neuroendocrine tumors in National Cancer Database (2006-15):



79.3% well-differentiated

11% mod differentiated

9.7% poorly differentiated

Size & Differentiation associated with:


Higher likelihood metastases



Tumors > 1.15 cm had substantially ↑ risk distant metastatic disease (13.8%)



Concors SJ et al. *Dis Colon Rectum* 2018;61(12):1372-79



2018 December

Natural History of Sessile Serrated Adenoma Polyps

SSA polyps: (CpG island methylation, BRAF mutations)



440 pts (with 668 SSAs) followed 2006-2015 at a single center



31% with multiple SSAs: (24% synchronous, 10% metachronous)

83% of SSAs Right Sided



Marked increase in additional polyps/dysplasia w/ >4 SSAs




45% had ≥1 colonoscopy with no prior SSA



Copyright © Wolters Kluwer Health, Inc. All rights reserved.


Neary PM et al. *Dis Colon Rectum* 2018;61(12):1380-85




2018 December

Impact of Disgust on Intentions to Undergo #ColorectalSurgery

Emotions may impact medical decisions




319 non-patients given:
Online stoma care info vs. No info




Stoma-Informed subjects had:

- Higher level Disgust** (4.08 vs. 2.35, $p < 0.001$)
- Lower surgery intent** (4.60 vs. 5.14, $p = 0.05$)
- Lower instruction recall** (13.75 vs. 14.36, $p = 0.03$)




Surgeons must account for the impact of **Disgust** as they counsel patients



Turner MC et al. *Dis Colon Rectum* 2018;61(12):1386-92


Copyright ©Wolters Kluwer Health, Inc. All rights reserved.




2018 December

Risk of Intra-Abdominal Sepsis After Ileocolonic Resection in Crohn's

621 patients with ileocolonic resection for Crohn's:




Triple Immunosuppression
(Steroid + Biologic + Immunomodulator)




Associated with:
Increased Risk Sepsis
O.R. = 3.53 (vs. none)

Prior Surgery Also Associated with Increased Risk Sepsis:
 $P < 0.01$



McKenna NP et al. *Dis Colon Rectum* 2018;61(12):1393-1402


Copyright ©Wolters Kluwer Health, Inc. All rights reserved.




2018 December

Thoracic Epidurals: Do they Enhance Recovery?


1,006 patients at single center:
815 epidural vs. 191 none




All patients managed with opioid-sparing ERAS protocol postop




No Difference in LOS
4 vs. 5 days, $p = 0.16$




No Difference in Opioid Use
135 vs. 110 OME, $p = 0.35$



Conclusion:
Routine Thoracic Epidural (in setting of ERAS protocol) is not recommended



Rosen DR et al. *Dis Colon Rectum* 2018;61(12):1403-9



2018 December

Predicting Risk of Readmission From Dehydration After Ileostomy

ACS NSQIP 2012-15:
8,064 patients w/ ileostomy

Risk of Readmission for Dehydration: **20.1%**

***Predictive Risk Factors:**

- ASA Class III
- Female
- IPAA
- Age \geq 65 Years
- Short LOS
- IBD
- HTN

**Used to create risk scoring model*

Chen SY et al. *Dis Colon Rectum* 2018;61(12):1410-17

Copyright ©Wolters Kluwer Health, Inc. All rights reserved.

2018 December

Use & Clinical Outcomes of Alvimopan with Bowel Resection

National Database Review:
2010-14

18,559 pts in each of two propensity-matched cohorts

2-15 doses Alvimopan vs. No drug (control)

Alvimopan:

- Reduced LOS by 0.62 days (4.62 vs. 5.24 days) $p < 0.001$
- Lower Rates of GI Complications/Ileus (12.15% vs. 16.5%) $p < 0.001$
- Lower Rates of other complications (vs. controls): UTI, Cardiac, Pulmonary, VTE, and Cerebral events

Steele SR et al. *Dis Colon Rectum* 2018;61(12):1418-25

Copyright ©Wolters Kluwer Health, Inc. All rights reserved.

2018 December

Ketorolac Use and Anastomotic Leak in Elective #ColorectalSurgery

Single Institution (Tertiary Referral Center):

566 patients w/ Ketorolac vs. 311 Controls (No Ketorolac)

No Difference in Anastomotic Leak Rates:
3.1 vs. 3.3% ($p=0.84$)

No difference in:

- Acute Kidney Injury
- Return to OR
- Readmission

Hawkins AT et al. *Dis Colon Rectum* 2018;61(12):1426-34

Copyright ©Wolters Kluwer Health, Inc. All rights reserved.

